Cost-effectiveness analysis of apatinib combined with adriamycin for second-line treatment of platinum-resistant recurrent ovarian cancer

ZHAN Shaoqing; LIU Xiaoya; ZHOU Jiaqi; CHEN Xia

doi:10.6039/j.issn.1001-0408.2024.10.15

您当前的位置：

首页 >

文章列表页 >

Cost-effectiveness analysis of apatinib combined with adriamycin for second-line treatment of platinum-resistant recurrent ovarian cancer

更新时间：2025-09-25

- Cost-effectiveness analysis of apatinib combined with adriamycin for second-line treatment of platinum-resistant recurrent ovarian cancer
- ZHONGGUO YAOFANG Vol. 35, Issue 10, Pages: 1238-1242(2024)
- 作者机构：
  
  南通市第一人民医院药剂科，江苏南通　226000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.10.15
  CLC： R956
- Received：19 September 2023，
  
  Revised：2024-04-27，
  
  Accepted：30 April 2024，
  
  Published：30 May 2024
- 稿件说明：
移动端阅览
詹少卿,柳小亚,周佳琦,等.阿帕替尼联合多柔比星二线治疗铂类耐药的复发性卵巢癌的成本-效果分析[J].中国药房,2024,35(10):1238-1242.

ZHAN Shaoqing,LIU Xiaoya,ZHOU Jiaqi,et al.Cost-effectiveness analysis of apatinib combined with adriamycin for second-line treatment of platinum-resistant recurrent ovarian cancer[J].ZHONGGUO YAOFANG,2024,35(10):1238-1242.
詹少卿,柳小亚,周佳琦,等.阿帕替尼联合多柔比星二线治疗铂类耐药的复发性卵巢癌的成本-效果分析[J].中国药房,2024,35(10):1238-1242. DOI： 10.6039/j.issn.1001-0408.2024.10.15.

ZHAN Shaoqing,LIU Xiaoya,ZHOU Jiaqi,et al.Cost-effectiveness analysis of apatinib combined with adriamycin for second-line treatment of platinum-resistant recurrent ovarian cancer[J].ZHONGGUO YAOFANG,2024,35(10):1238-1242. DOI： 10.6039/j.issn.1001-0408.2024.10.15.

摘要

目的

从中国卫生体系角度评价阿帕替尼联合多柔比星二线治疗铂类药物耐药的复发性卵巢癌（OC）的经济性。

方法

基于APPROVE试验和相关文献数据构建三状态分区生存模型，模型模拟时限为10年，循环周期为4周，成本和效果的贴现率为5%。以成本和质量调整生命年（QALYs）作为模型产出指标并计算增量成本-效果比（ICER），评价阿帕替尼联合多柔比星对比多柔比星单独化疗二线治疗铂类药物耐药的复发性OC的经济性，并采用单因素敏感性分析、概率敏感性分析以及情境分析验证基础分析结果的稳健性。

结果

基础分析结果表明，与单独化疗相比，阿帕替尼联合多柔比星方案的ICER为124 678.25元/QALY，低于本研究设定的意愿支付（WTP）阈值（3倍我国2022年人均国内生产总值257 094元）。情境分析结果显示，随着模拟时限的延长，阿帕替尼联合多柔比星方案的ICER逐渐降低，降幅逐渐减小，均低于本研究设定的WTP阈值。单因素敏感性分析结果显示，对ICER影响程度最大的因素包括疾病进展状态效用值、体表面积、贴现率和最佳支持治疗成本等。概率敏感性分析结果表明，在本研究设定的WTP阈值下，阿帕替尼联合多柔比星方案具有经济性的概率超过99%。

结论

从中国卫生体系角度，以3倍我国2022年人均国内生产总值为WTP阈值，阿帕替尼联合多柔比星对比多柔比星单独化疗二线治疗铂类药物耐药的复发性OC更具经济性。

Abstract

OBJECTIVE

To evaluate the cost-effectiveness of apatinib combined with adriamycin in the second-line chemotherapy of platinum-resistant recurrent ovarian cancer （OC） from the perspective of the health system in China.

METHODS

A three-state partitioned survival model was constructed based on the APPROVE clinical trial and related literature data， with a model simulation time frame of 10 years and a 4-week cycle， and both cost and utility values were discounted using a 5% discount rate. Cost and quality-adjusted life years （QALYs） were used as a model output indicator and the incremental cost-effectiveness ratio（ICER） was calculated to evaluate the cost-effectiveness of apatinib combined with adriamycin versus adriamycin chemotherapy in the second-line treatment of platinum-resistant recurrent OC. One-way sensitivity analysis， probability sensitivity analysis and scenario analysis were used to verify the robustness of the base-case analysis results.

RESULTS

The results of base-case analysis indicated that compared with chemotherapy alone， ICER of patients receiving apatinib combined with adriamycin was 124 678.25 yuan/QALY， which was less than willingness-to-pay （WTP） threshold set in this study [3 times per capita gross domestic product （GDP） of China in 2022 （257 094 yuan）]. The results of scenario analysis showed that， with the extension of the simulation time limit， the ICER of apatinib combined with adriamycin was gradually reduced， and the decline was gradually reduced， but both were less than WTP threshold. The results of single factor sensitivity analysis showed that the factors that had the greatest impact on ICER were the utility value of progression， body surface area， discount rate，and the cost of best supportive treatment， etc. The results of probability sensitivity analysis showed that under WTP threshold set in this study， the economic probability of apatinib combined with adriamycin was about 99%.

CONCLUSIONS

From the perspective of China’s health system， using three times the per capita GDP in 2022 as the WTP threshold， the combination of apatinib and adriamycin is more cost-effective than adriamycin alone in second-line chemotherapy for platinum-resistant recurrent OC.

关键词

Keywords

references

SUNG H ， FERLAY J ， SIEGEL R L ， et al . Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 .

HENNESSY B T ， COLEMAN R L ， MARKMAN M . Ovarian cancer [J ] . Lancet ， 2009 ， 374 （ 9698 ）： 1371 - 1382 .

国家卫生健康委办公厅．国家卫生健康委办公厅关于印发肿瘤和血液病相关病种诊疗指南（2022年版）的通知 [EB/OL ] ．（ 2022-04-11 ）[ 2024-02-01 ] . http：//www.nhc.gov.cn/yzygj/s2911/202204/a0e67177df1f439898683e133-3957c74.shtml http://www.nhc.gov.cn/yzygj/s2911/202204/a0e67177df1f439898683e133-3957c74.shtml .

The General Office of the National Health Commission . Notice of the General Office of the National Health Commission on the issuance of guidelines for the diagnosis and treatment of tumor and blood diseases（2022 edition） [EB/OL ] .（ 2022-04-11 ）[ 2024-02-01 ] . http：//www.nhc.gov.cn/yzygj/s2911/202204/a0e67177df1f439898683e133395-7c74.shtml http://www.nhc.gov.cn/yzygj/s2911/202204/a0e67177df1f439898683e133395-7c74.shtml .

WANG T T ， TANG J ， YANG H Y ， et al . Effect of apatinib plus pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone on platinum-resistant recurrent ovarian cancer：the APPROVE randomized clinical trial [J ] . JAMA Oncol ， 2022 ， 8 （ 8 ）： 1169 - 1176 .

刘国恩 . 中国药物经济学评价指南：2020 [M ] . 北京：中国市场出版社， 2020 ： 1 - 8 .

LIU G E . Guidelines for pharmaceutical economics eva-luation in China：2020 [M ] . Beijing ： China Market Press ， 2020 ： 1 - 8 .

MENG R ， ZHOU T ， SHI F H ， et al . Cost-utility analysis of pembrolizumab in the second-line treatment of advanced hepatocellular carcinoma based on two models [J ] . China Pharm ， 2021 ， 32 （ 22 ）： 2761 - 2766 .

CASE A S ， ROCCONI R P ， PARTRIDGE E E ， et al . A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer [J ] . Gynecol Oncol ， 2007 ， 105 （ 1 ）： 223 - 227 .

ZHAN M ， XU T ， ZHENG H R ， et al . Cost-effectiveness analysis of pembrolizumab in patients with advanced esophageal cancer based on the KEYNOTE-181 study [J ] . Front Public Health ， 2022 ， 10 ： 790225 .

WU B ， DONG B J ， XU Y J ， et al . Economic evaluation of first-line treatments for metastatic renal cell carcinoma：a cost-effectiveness analysis in a health resource-limited setting [J ] . PLoS One ， 2012 ， 7 （ 3 ）： e32530 .

SHI G H ， PARK S H ， REN H Y ， et al . Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China [J ] . J Med Econ ， 2018 ， 21 （ 12 ）： 1150 - 1158 .

BALL G ， XIE F ， TARRIDE J E . Economic evaluation of bevacizumab for treatment of platinum-resistant recurrent ovarian cancer in Canada [J ] . Pharmacoecon Open ， 2018 ， 2 （ 1 ）： 19 - 29 .

SHU Y M ， LIU Y X ， HE X C ， et al . Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in China [J ] . Front Pharmacol ， 2022 ， 13 ： 818579 .

LIN Y S ， QIN S K ， LI Z Y ， et al . Apatinib vs placebo in patients with locally advanced or metastatic，radioactive iodine-refractory differentiated thyroid cancer：the REALITY randomized clinical trial [J ] . JAMA Oncol ， 2022 ， 8 （ 2 ）： 242 - 250 .

LI J ， QIN S K ， XU J M ， et al . Randomized，double-blind，placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction [J ] . J Clin Oncol ， 2016 ， 34 （ 13 ）： 1448 - 1454 .

QIN S K ， LI Q ， GU S Z ， et al . Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma（AHELP）：a multicentre，double-blind， randomised，placebo-controlled，phase 3 trial [J ] . Lancet Gastroenterol Hepatol ， 2021 ， 6 （ 7 ）： 559 - 568 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Cost-effectiveness analysis of sacituzumab tirumotecan versus single-agent chemotherapy in second-line and later-line treatment for metastatic triple-negative breast cancer

Analysis of cost-effectiveness of amivantamab combined with chemotherapy in the treatment of EGFR-mutated advanced non-small cell lung cancer

Cost-effectiveness analysis of gonadotropin-releasing hormone analogue combined with recombinant human growth hormone in the treatment of central precocious puberty

Clinical evaluation of elderly patients with sarcopenia receiving Shenling baizhu powder combined with nutrition and exercise intervention

Cost-effectiveness analysis of tislelizumab combined with chemotherapy as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

Related Author

LIU Guoqiang

GAO Ning

FENG Bing

GAO Shengnan

ZHANG Yuxi

ZHANG Ranran

WANG Xianying

LIANG Miao

Related Institution

Hebei Society for Integrated Drug and Health Technology Assessment

Dept. of Clinical Pharmacy， Hebei Medical University Third Hospital

Dept. of Pharmacy， Hebei Medical University Third Hospital

Evidence-based Pharmacy Center， West China Second Hospital， Sichuan University

Evidence-based Medicine Center， West China Hospital， Sichuan University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰